Senolytics: Navitoclax

Navitoclax is a cancer drug that has recently been shown to have senolytic properties as this research paper shows here and another group also confirmed here.

However Navitoclax has potentially serious side effects and can cause bleeding by affecting platelets and can cause neutropenia, while newer similar drugs may have less of these effects.Whilst these findings are of interest to us we are far more interested in testing the potential of second generation drugs based on this drug but with far less off target side effects. However this research is an interesting proof of concept and has spurred the race to discover better candidates for senolytic use.

Better Senolytics are sure to appear in due course with a number of companies engaging in developing even more potent candidates.